Bayer continues positive business momentum The Bayer Group continued its positive business momentum in the 3rd quarter of 2013, with substantial contributions from the entire life Science businesses HealthCare and CropScience. Reported product sales of the Bayer Group had been level yr on year at EUR 9,643 million . Adjusted for currency and portfolio results , product sales grew by 6 read .0 %. EBIT improved by a considerable 47.5 % to EUR 1,221 million due partly to a drop in net special charges to EUR 99 million .
The organization's goal is to find and manufacture items which will improve human wellness worldwide by diagnosing, treating and avoiding diseases. © 2014 Bayer Health care Pharmaceuticals Inc. BAYER, the Bayer Cross, and Xofigo are authorized trademarks of Bayer. Forward-Looking Statement This news discharge may contain forward-searching statements predicated on current assumptions and forecasts created by Bayer Group or subgroup administration. Various known and unidentified risks, uncertainties and additional factors may lead to material variations between your actual future results, finances, development or overall performance of the ongoing organization and the estimates provided here.